Effect of Infliximab Treatment on QT Intervals in Patients With Ankylosing Spondylitis

ŞENEL S., Cobankara V., Taskoylu O., Guclu A., Evrengul H., Kaya M. G.

JOURNAL OF INVESTIGATIVE MEDICINE, cilt.59, sa.8, ss.1273-1275, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 8
  • Basım Tarihi: 2011
  • Doi Numarası: 10.2310/jim.0b013e3182330720
  • Dergi Adı: JOURNAL OF INVESTIGATIVE MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1273-1275
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Background: Cardiovascular complications are one of the most common and the most serious extraskeletal manifestations of ankylosing spondylitis (AS). Infliximab, a monoclonal antibody against tumor necrosis factor, is widely used in the treatment of AS. QT dispersion (QTd), which relates to left ventricular function and is used as an index of cardiac dysrhythmia, may be useful as a prognostic guide. Early detection of possible cardiac involvement may not be clinically evident, whereas it may be detected by electrocardiography.